EGFR and head and neck squamous cell carcinoma: The use of the EGFR inhibitor, Cetuximab, in combination with radio and chemotherapy, represents the first targeted therapy scheme approved by the FDA as a standard of care for patients with recurrent or metastatic HNSCC [5,6,27,36].